Wolverine Legal Status, FDA 503A Category, and Compounding Access
FDA's current record shows that the 503A nominations for BPC-157 and TB-500 were withdrawn. That record does not determine a patient's prescription: a licensed U.S. clinician assesses the request, may decline it, and must account for the patient's state and the treatment. The record is kept here in the title block.
Where access stands today, and what is not yet known
Wolverine legal status starts with a meeting that is now behind us: the FDA Pharmacy Compounding Advisory Committee (PCAC) met on July 23-24, 2026 with these peptides on its agenda as candidates for the 503A bulks list [13]. The published agenda concerns bulk-substance evaluation, a separate question from an individual prescription.
The present-tense fact is more tangled. FDA previously placed the blend's two peptides — BPC-157 and TB-500 — in Category 2 for 503A compounding; their nominations now appear in its withdrawn table. The withdrawn entries retain FDA's safety concerns; withdrawal grants neither drug approval nor compounding permission [11]. Category 2 substances fall outside the interim enforcement-discretion policy [12]; a withdrawn nomination does not create an authorization to compound.
Nothing on this sheet states a reclassification as done, dated, or certain. The July 2026 meeting was an advisory discussion of substances under evaluation, not a decision, and FDA had published no record of its votes as of September 2026 [13]. Wolverine prescribing already occurs within U.S. clinical care, with acceptance determined separately for each patient and options restricted by state and treatment. This page is general information about the regulatory landscape, not medical or legal advice.
Where the blend now appears in FDA's compounding record
Compounding in the U.S. runs on two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally under a prescription for an individual patient. Section 503B covers FDA-registered outsourcing facilities that compound larger batches under cGMP-style oversight [12].
A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. Substances not yet on a bulks list are evaluated by FDA through a public nomination process with input from the PCAC [12].
FDA's interim policy sorted nominated substances into categories. Category 1 substances may be eligible for the bulks list and are covered by FDA's enforcement-discretion policy while under evaluation. Category 2 substances are those FDA identified as raising significant safety risks; they are not covered by that policy, and FDA stated it would consider taking action against a compounder using a Category 2 substance [12]. For BPC-157 and TB-500, FDA cited concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and characterization [11].
What is the FDA 503A status of Wolverine? {#fda-503a-status-of-wolverine}
FDA now records both Wolverine ingredients among withdrawn bulk-substance nominations, outside its Category 2 table. BPC-157 and the thymosin beta-4 fragment LKKTETQ, also known as TB-500, remain on FDA's page of bulk substances that may present significant safety risks [11]. Neither component, nor the blend, is an FDA-approved medicine [12].
How legally compounded peptide access works
Where a peptide is eligible to be compounded, lawful access in the U.S. follows one general pathway. A compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription [12].
From there, the prescription is dispensed by a state-licensed 503A compounding pharmacy (patient-specific) or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility [12]. Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued. It is a route to a licensed-prescriber consultation, not a separate legal status: telehealth does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate prescriber-patient relationship and a valid prescription [12].
The ingredient-eligibility caveat is the part that matters most for the Wolverine blend. A compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules — a USP/NF monograph, a component of an approved drug, or a place on the applicable FDA bulks list. Category 2 entries do not receive the interim policy's enforcement discretion [12]. BPC-157 and TB-500 appear instead as withdrawn nominations with safety notes retained; that entry confers no permission to compound either ingredient [11]. This page gives no dosing and is general information rather than medical or legal advice.
Prescription access for Wolverine, the BPC-157 and TB-500 blend, is a separate question from the evidence: Promise Peptides prescribes it now; mypromise.com is its address, and the product cannot be dispensed without a prescription. A licensed clinician practicing in the U.S. assesses the individual request and may refuse to prescribe. This service takes U.S. patients only, with its options changing according to their state and the proposed treatment. The compounded product has no FDA approval.
FDA approval and WADA status
Beyond compounding eligibility, two further status questions recur for the blend.
Are BPC-157 and TB-500 FDA approved or banned by WADA? {#fda-approved-or-banned-by-wada}
Neither is FDA-approved for human use, and the blend has no approved indication [12]. Both are prohibited by the World Anti-Doping Agency: BPC-157 under the S0 non-approved-substances category, and TB-500 / Thymosin Beta-4 under prohibited peptide and tissue-repair categories. FDA's earlier Category 2 entries for both substances cited significant safety risks [11].
Is Wolverine legal? {#is-wolverine-legal}
Status depends on jurisdiction and context. Neither constituent is an FDA-approved medicine, and both are WADA-prohibited in sport. FDA lists both nominations as withdrawn with the safety concerns still present; this is neither drug approval nor permission to compound [11] [12]. Research-use and human-use contexts are treated differently.
Can you get BPC-157 from a compounding pharmacy? {#bpc-157-from-a-compounding-pharmacy}
The BPC-157 nomination appears in FDA's withdrawn table, with the earlier safety rationale intact and no authorization to compound conferred by withdrawal [11]. BPC-157 was on the agenda of the July 23-24, 2026 PCAC meeting as a candidate for the bulks list; a committee discussion is not an authorization to compound [13].
What are the side effects of BPC-157 and TB-500? {#side-effects-of-bpc-157-and-tb-500}
There is no controlled human safety dataset for the blend. A 2025 BPC-157 systematic review explicitly found no clinical safety data [8]; 2025-2026 reviews note that unapproved musculoskeletal peptides can carry potential for serious harm and operate largely outside regulatory oversight [9]. Long-term human safety of the combination is unknown.